Pharmaceuticals - Niger

Niger

The Pharmaceuticals market in Niger is expected to experience significant growth in the coming years.
By 2025, it is projected that the market's revenue will reach a substantial amount of US$139.00m.
among the various markets within the market, Oncology Drugs holds the largest share.
It is estimated that by 2025, the market volume for Oncology Drugs will reach US$20.45m.
Over the forecast period from 2025 to 2029, the Pharmaceuticals market in Niger is expected to exhibit a steady annual growth rate (CAGR) of 4.06%.
This growth will result in a market volume of US$163.00m by the end of 2029.
When compared to other countries globally, United States is projected to generate the highest revenue in the Pharmaceuticals market.
In 2025 alone, United States is expected to generate a staggering revenue of US$660.00bn.
Niger's pharmaceutical market is experiencing a surge in demand for affordable and accessible healthcare products.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Next generation therapies are also part of the Pharmaceuticals market and include gene therapy, cell therapy, and nucleic acid therapy. Cell therapies involve the use of living cells to replace or repair damaged tissues within the patient's body, or to modify cells to perform specific functions. Gene therapies focus on altering a patient’s genetic material to regulate the production of certain proteins. Nucleic acid therapies use short strands of DNA or RNA to inhibit the production of harmful proteins associated with diseases and promote the generation of therapeutic proteins. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

Niger, a landlocked country in West Africa, is a low-income country with a population of over 24 million people. The country has a challenging healthcare system with limited access to essential medicines, including pharmaceuticals.

Customer preferences: The majority of the population in Niger lives in rural areas, where access to healthcare facilities is limited. As a result, many people rely on traditional medicine or informal markets to access medicines. The cost of pharmaceuticals is also a significant barrier to access, with many people unable to afford essential medicines.

Trends in the market: The pharmaceutical market in Niger is relatively small, with limited local manufacturing and a heavy reliance on imports. The market is dominated by generic medicines, with a focus on essential medicines for communicable diseases such as malaria, tuberculosis, and HIV/AIDS. The demand for pharmaceuticals is increasing, driven by a growing population and an increasing burden of non-communicable diseases such as diabetes and hypertension.

Local special circumstances: Niger faces several challenges in ensuring access to essential medicines. The country has a weak healthcare system, with limited infrastructure and human resources. There are also significant logistical challenges in distributing medicines to remote areas, where the majority of the population lives. Additionally, the country faces security challenges, particularly in the border regions, which can impact the availability and distribution of medicines.

Underlying macroeconomic factors: Niger is a low-income country with a largely agrarian economy. The country is heavily reliant on foreign aid, which accounts for a significant portion of the government budget. The pharmaceutical market is subject to fluctuations in exchange rates and international trade policies, which can impact the availability and affordability of medicines. The government has made efforts to increase access to essential medicines through initiatives such as the National Medicines Policy, which aims to improve the regulation and availability of medicines in the country. However, significant challenges remain in ensuring access to essential medicines for all Nigeriens.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.